ClinicalTrials.gg
CompletedNCT02668393Updated Jan 29, 2021Results posted

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

A Phase 1 interventional study of Docetaxel and Nintedanib in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
158th of 188
14 · median 50
Started
2016
with 2 others
Phase 1
20 of 198
1 open now
Registered
164th of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 158th largest by enrollment of the 188 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 1, and was the 164th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients with histologically/ confirmed locally advanced (Stage IIIB) or (Stage IV) lung adeno carcinoma after failure of platinum - based chemotherapy (patients with non-target lesion only are eligible).

First line chemotherapy may include continuation or switch maintenance therapy. One prior and/or neoadjuvant chemotherapy line is accepted. Prior immunotherapy is allowed.

  • inferior or equal to 1 at screening.
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Patients who have received more than one (i.e. second or third line chemotherapy) for advanced or NSCLC.
  • Patients known to be positive for activating Epidermal Growth Factor Receptor (EGFR) mutation or patients known to be positive for ALK translocation
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Other
    Level 0

    Nintedanib low dose with docetaxel

    Drug: Docetaxel · Drug: Nintedanib

  • Other
    Level 1

    Nintedanib medium dose with docetaxel

    Drug: Docetaxel · Drug: Nintedanib

  • Other
    Level 2

    Nintedanib high dose with docetaxel

    Drug: Docetaxel · Drug: Nintedanib

  • Other
    Level 3

    Nintedanib continuous high dose with docetaxel

    Drug: Docetaxel · Drug: Nintedanib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel

    Maximum tolerated dose (MTD) of nintedanib administered in combination with docetaxel. The MTD was defined as the highest dose combination studied for which the incidence of DLTs was no more than 1 out of 6 subjects experiencing a DLT during the first treatment cycle i.e. the incidence of DLTs was no more than 17%. In case dose escalation reached dose level 3 (200 mg bid nintedanib administered without interruption on days of docetaxel infusion) and no more than 1 out of 6 subjects experienced a DLT during the first 28-day cycle at this dose level, dose level 3 was considered the MTD.

    Time frame: First treatment cycle, the first 28 days following the start of trial medication.

  2. Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle

    Number of participants with DLT occurring during the first treatment cycle. DLT was defined as any of the following adverse events related to nintedanib: * Non-haematological drug-related Common Terminology Criteria for AEs (CTCAE) grade 3 or greater * diarrhoea CTCAE grade 2 for \>7 days despite supportive care * nausea CTCAE grade 3 or greater despite supportive care * vomiting CTCAE grade 2 or greater despite supportive care * increase in Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) to CTCAE grade 3 or greater * A increase in ALT and/or AST to CTCAE grade 2 or greater in conjunction with * total bilirubin increase of CTCAE grade 1 or greater * Platelets \<50 000/mm3 with bleeding (CTCAE ≥3) * neutropenia of any grade or duration accompanied by fever \>38.5°C * neutropenia grade 4 without fever of \>7 days duration * Inability to resume nintedanib dosing within 21 days after stopping due to toxicity.

    Time frame: First treatment cycle, the first 28 days following the start of trial medication.

07

Results

Posted Jan 29, 2021
Limitations and caveats
Recruitment was prematurely discontinued after dose level 2 (200 milligram) due to difficulties in recruiting subjects.

Participant flow

This study is an open-label Phase I of oral nintedanib plus weekly docetaxel therapy in subjects with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first-line chemotherapy.

Participant flow — Overall Study
Milestone150 mg Nintedanib + Docetaxel200 mg Nintedanib + Docetaxel
Started77
Completed01
Not completed76
Withdrew: Progressive disease63
Withdrew: Adverse event02
Withdrew: Withdrawal from the trial01
Withdrew: Lack of benefit and side effects10

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel

Maximum tolerated dose (MTD) of nintedanib administered in combination with docetaxel. The MTD was defined as the highest dose combination studied for which the incidence of DLTs was no more than 1 out of 6 subjects experiencing a DLT during the first treatment cycle i.e. the incidence of DLTs was no more than 17%. In case dose escalation reached dose level 3 (200 mg bid nintedanib administered without interruption on days of docetaxel infusion) and no more than 1 out of 6 subjects experienced a DLT during the first 28-day cycle at this dose level, dose level 3 was considered the MTD.

Time frame:
First treatment cycle, the first 28 days following the start of trial medication.
Reported as:
Number · milligram
Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel
milligramNintedanib + Docetaxel
Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With DocetaxelNA
PrimaryNumber of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle

Number of participants with DLT occurring during the first treatment cycle. DLT was defined as any of the following adverse events related to nintedanib: * Non-haematological drug-related Common Terminology Criteria for AEs (CTCAE) grade 3 or greater * diarrhoea CTCAE grade 2 for \>7 days despite supportive care * nausea CTCAE grade 3 or greater despite supportive care * vomiting CTCAE grade 2 or greater despite supportive care * increase in Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) to CTCAE grade 3 or greater * A increase in ALT and/or AST to CTCAE grade 2 or greater in conjunction with * total bilirubin increase of CTCAE grade 1 or greater * Platelets \<50 000/mm3 with bleeding (CTCAE ≥3) * neutropenia of any grade or duration accompanied by fever \>38.5°C * neutropenia grade 4 without fever of \>7 days duration * Inability to resume nintedanib dosing within 21 days after stopping due to toxicity.

Time frame:
First treatment cycle, the first 28 days following the start of trial medication.
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle
Participants150 mg Nintedanib + Docetaxel200 mg Nintedanib + Docetaxel
Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle11

Adverse events

Collected over From first administration of study drug till the last administration + a residual effect period (REP) of 28 days, up to 330 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150 mg Nintedanib + Docetaxel0/7 (0%)3/7 (42.9%)6/7 (85.7%)
200 mg Nintedanib + Docetaxel0/7 (0%)2/7 (28.6%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
Event150 mg Nintedanib + Docetaxel200 mg Nintedanib + Docetaxel
DyspnoeaRespiratory, thoracic and mediastinal disorders2/70/7
NauseaGastrointestinal disorders1/70/7
General physical health deteriorationGeneral disorders0/71/7
EmpyemaInfections and infestations0/71/7
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/71/7
CoughRespiratory, thoracic and mediastinal disorders1/70/7
Most frequent other events
Showing 10 of 59
Most frequent other events
Event150 mg Nintedanib + Docetaxel200 mg Nintedanib + Docetaxel
DiarrhoeaGastrointestinal disorders5/74/7
AnaemiaBlood and lymphatic system disorders3/71/7
NauseaGastrointestinal disorders2/73/7
CoughRespiratory, thoracic and mediastinal disorders3/70/7
EpistaxisRespiratory, thoracic and mediastinal disorders3/71/7
ConstipationGastrointestinal disorders2/70/7
VomitingGastrointestinal disorders0/72/7
AstheniaGeneral disorders2/70/7
FatigueGeneral disorders2/72/7
Mucosal inflammationGeneral disorders2/70/7

Baseline characteristics

Treated set (TS): all subjects who received at least one dose of study medication. The TS was used for all safety and efficacy analyses

Age, Continuous
Age, Continuous(years)150 mg Nintedanib + Docetaxel200 mg Nintedanib + DocetaxelTotal
Mean67.0 ± 7.660.3 ± 7.863.6 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)150 mg Nintedanib + Docetaxel200 mg Nintedanib + DocetaxelTotal
Female224
Male5510
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)150 mg Nintedanib + Docetaxel200 mg Nintedanib + DocetaxelTotal
White5510
Not reported due to local law restrictions224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)150 mg Nintedanib + Docetaxel200 mg Nintedanib + DocetaxelTotal
Not Hispanic or Latino5510
Not reported due to local law restrictions224
08

Study locations

4 sites
  • HOP d'Angers
    Angers, 49 933, France
  • HOP Jean Minjoz
    Besançon, 25030, France
  • Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
    Großhansdorf, 22927, Germany
  • Krankenhaus Martha-Maria Halle-Dölau gGmbH
    Halle/Saale, 06120, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Nov 2019, 44 months.

Results were first posted in Jan 2021, 1 year 2 months after primary completion.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 44 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2016
First posted
Jan 29, 2016
StartActual
Mar 7, 2016
Primary completionActual
Nov 27, 2019
CompletionActual
Nov 27, 2019
Results first posted
Jan 29, 2021
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02668393
Responsible party
Sponsor
First posted
Jan 29, 2016
Start date
Mar 7, 2016
Primary completion
Nov 27, 2019
Completion
Nov 27, 2019
Results posted
Jan 29, 2021
Last update
Jan 29, 2021

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Nintedanib

Start the discussion